Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jan;34(1):48-57.
doi: 10.1016/j.hlc.2024.05.014. Epub 2024 Nov 26.

Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022

Paul Geenty  1 , Nicholas Davidson  2 , Natasha Gorrie  3 , Nicole Bart  3 , Jay Baumwol  2 , Timothy Sutton  4 , Fiona Kwok  5 , James L Hare  6 , Kah Yong Peck  7 , Dariusz Korczyk  8 , Simon D J Gibbs  9 , Liza Thomas  10 ; Cardiac Subcommittee of the Australian Amyloidosis Network
Affiliations
Multicenter Study

Transthyretin Cardiac Amyloidosis in Australia and New Zealand-A Multi-Site Snapshot for 2022

Paul Geenty et al. Heart Lung Circ. 2025 Jan.

Abstract

Objective: To estimate the burden of transthyretin cardiac amyloidosis (ATTR-CA) through a cross- sectional 'snapshot' of Australian Amyloidosis Network (AAN) and New Zealand (NZ) specialist amyloidosis clinics.

Design, setting & participants: A prospective survey was performed of seven AAN/ specialist amyloidosis clinics across Australia and NZ. All centres were invited to contribute data; participating centres provided clinical and demographic data for patients with ATTR-CA reviewed in the 2022 calendar year. Patients with new or previously confirmed ATTR-CA reviewed in the 2022 calendar year were included. Diagnosis was established through a positive cardiac scintigraphy scan in the absence of a monoclonal gammopathy or through a cardiac biopsy staining positive with transthyretin (TTR).

Results: A total of 515 patients were reviewed across seven sites. A total of 302/515 (59%) were wild type TTR (ATTRwt), 63/515 (12%) were variant ATTR (ATTRv) and the remaining 150 (29%) had not undergone genetic testing at the time of data collection. A total of 455/515 (88%) patients were male. Compared to ATTRwt, patients with ATTRv had smaller left ventricular (LV) wall thickness (IVSd 14±3 mm vs 16±3mm, p<0.001), and better LV systolic function (LVGLS -15.4±5% vs -11.7±3%, p<0.001). Most patients, 387/515 (75%) were on at least one ATTR specific treatment, including EGCG (157), diflunisal (139), doxycycline (68) and tafamidis (78), acoramidis (33) and gene silencer therapies or monoclonal antibodies (23).

Conclusion: A significant number of patients with ATTR-CA are seen in specialist amyloidosis clinics across Australia and NZ. Most patients received specific amyloidosis therapy, thorough enrollment in clinical trials. With increased recognition of amyloidosis and newer therapies becoming available, the volume of patients seen in these clinics is likely to increase.

Keywords: Amyloidosis; Cardiomyopathy; Infiltrative cardiomyopathy; Transthyretin.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interests J.B., N.D., D.K., F.K., K.Y.P., and T.S. declare no relevant disclosures. N.B receives funding from the Ramaciotti Foundations and Fullbright Commission, is a member of the advisory board for Bristol Myers Squibb, and engages in research funded by Novartis and Pfizer. P.G is supported by The National Heart Foundation of Australia PhD Scholarship. S.G receives honoria for speaking engagements with Pfizer, BridgeBio, Alexion/AstraZeneca, Ionis, Intellia, and Attralus, is a member of the advisory board for steering committee payments from Pfizer, and has involvement in clinical trials with Pfizer, Alexion. J.H is a member of the advisory board for Pfizer and has involvement in clinical trials with Pfizer. L.T is a member of the advisory boards for Boehringer Ingelheim, Novartis, Sanofi, and receives research funding from Janssen, Pfizer, Bayer, and Medical Research Future Fund.

Publication types

Supplementary concepts